HOW PATIENTS EXPERIENCE CANCER CARE IN CANADA: NEW REPORT A new report published by the Canadian Partnership Against Cancer illustrates the experiences of patients from the time cancer is suspected through adjusting to a “new normal” after treatment ends. This is the first in a series presenting national survey data (more…)
ARCC is pleased to announce the launch of our 2018 Seed Grant competition! The purpose of the ARCC Seed Grant program is to provide initial ‘start-up’ funding for new or existing researchers to conduct research. The proposed research is to be in an area that is relevant to ARCC, specifically demonstrating (more…)
The Canadian Centre for Applied Research in Cancer Control (ARCC) is proud to share work led by one of our HTA Program Leads, Dr. Claire de Oliveira, and funded by ARCC. The economic burden of (more…)
CCO is calling for proposals from investigators, scientists and clinicians to undertake research projects in a number of priority areas. View the full announcement here Application Deadline: Monday, January 22, 2018 at 11:59 p.m. EST Funds Available: Total funding available for the 2018/19 competition varies (more…)
ICER is a trusted non-profit organization that evaluates evidence on the value of medical tests, treatments and delivery system innovations and moves that evidence into action to improve the health care system. To accomplish this goal ICER performs analyses on effectiveness and costs; develops reports using innovative methods that make (more…)
The results for the 2017 CIHR-PHSI for Cancer Control research have been formally announced, and ARCC is proud to have significant involvement in the work to come. Four of the six announced projects are led by ARCC members, including projects headed by both ARCC co-directors. This represents a significant investment by (more…)
re-posted from http://www.partnershipagainstcancer.ca/new-vice-president-cancer-control/ The Canadian Partnership Against Cancer (the Partnership) has announced the appointment of Dr. Craig Earle as Vice-President, Cancer Control effective November 1, 2017.
In a recent paper published in the Journal of Clinical Oncology and supported by ARCC, researchers examined whether the ASCO Value Framework and the ESMO Magnitude of Clinical Benefit Scale measure similar constructs of clinical benefit. They also looked at how both relate to quality-adjusted life-years, and funding recommendations in (more…)